Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
The Role of Distinct Subsets of Macrophages in the Pathogenesis of Ms and the Impact of Different Therapeutic Agents on These Populations Publisher Pubmed



Radandish M1 ; Khalilian P1 ; Esmaeil N1, 2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  2. 2. Environment Research Center, Research Institute for Primordial Prevention of Non-Communicable Disease, Isfahan University of Medical Sciences, Isfahan, Iran

Source: Frontiers in Immunology Published:2021


Abstract

Multiple sclerosis (MS) is a demyelinating inflammatory disorder of the central nervous system (CNS). Besides the vital role of T cells, other immune cells, including B cells, innate immune cells, and macrophages (MФs), also play a critical role in MS pathogenesis. Tissue-resident MФs in the brain’s parenchyma, known as microglia and monocyte-derived MФs, enter into the CNS following alterations in CNS homeostasis that induce inflammatory responses in MS. Although the neuroprotective and anti-inflammatory actions of monocyte-derived MФs and resident MФs are required to maintain CNS tolerance, they can release inflammatory cytokines and reactivate primed T cells during neuroinflammation. In the CNS of MS patients, elevated myeloid cells and activated MФs have been found and associated with demyelination and axonal loss. Thus, according to the role of MФs in neuroinflammation, they have attracted attention as a therapeutic target. Also, due to their different origin, location, and turnover, other strategies may require to target the various myeloid cell populations. Here we review the role of distinct subsets of MФs in the pathogenesis of MS and different therapeutic agents that target these cells. © Copyright © 2021 Radandish, Khalilian and Esmaeil.
Related Docs
View other Related Docs
1. Therapeutic Targeting of Chemokines and Chemokine Receptors in Multiple Sclerosis: Opportunities and Challenges, CNS and Neurological Disorders - Drug Targets (2018)
2. Multiple Sclerosis: Pathophysiology, Clinical Features, Diagnosis, and Management, Neuroinflammation (2011)
3. Roles of Gm-Csf in the Pathogenesis of Autoimmune Diseases: An Update, Frontiers in Immunology (2019)
4. Micrornas: Key Modulators of Disease-Modifying Therapies in Multiple Sclerosis : Pancreatic Cancer Is One of the Lethal Malignant Tumours in the World.In This Study, We Investigated the Car T-Cell Therapy of Pancreatic Cancer, International Reviews of Immunology (2020)
5. The Role of Extracellular Vesicles and Microparticles in Central Nervous System Disorders: Mechanisms, Biomarkers, and Therapeutic Potential, Cellular and Molecular Neurobiology (2024)
6. Multiple Sclerosis: Clinical Features, Pathophysiology, Neuroimaging and Future Therapies, Future Neurology (2009)
7. A Novel Approach to Discriminate Subgroups in Multiple Sclerosis, Iranian Journal of Allergy, Asthma and Immunology (2016)
8. Effect of Different Treatments on Retinal Thickness Changes in Patients With Multiple Sclerosis: A Review, CNS Neuroscience and Therapeutics (2025)
Experts (# of related papers)
View all Related Experts
Masoud Etemadifar (32)
Vahid Shaygannejad (27)
Other Related Docs
9. Nose to Brain Delivery of Ibudilast Micelles for Treatment of Multiple Sclerosis in an Experimental Autoimmune Encephalomyelitis Animal Model, International Journal of Pharmaceutics (2023)
10. Cutting Edge: Metabolic Immune Reprogramming, Reactive Oxygen Species, and Cancer, Journal of Cellular Physiology (2021)
11. Comparison of the Expression of Mir-326 Between Interferon Beta Responders and Non-Responders in Relapsing-Remitting Multiple Sclerosis, Cell Journal (2020)
12. The Role of Cobalamin on Interleukin 10, Osteopontin, and Related Micrornas in Multiple Sclerosis, Iranian Journal of Allergy, Asthma and Immunology (2022)
13. Obesity and Adipose Tissue-Derived Cytokines in the Pathogenesis of Multiple Sclerosis, Endocrine, Metabolic and Immune Disorders - Drug Targets (2022)
14. Microrna-29B Variants and Mxa Expression Change During Interferon Beta Therapy in Patients With Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis and Related Disorders (2019)
15. Multiple Sclerosis: Pathogenesis, Symptoms, Diagnoses and Cell-Based Therapy, Cell Journal (2017)
16. Multiple Sclerosis and Cerebral Endothelial Dysfunction: Mechanisms, Pathophysiology (2011)
17. The Role of Nk and Nkt Cells in the Pathogenesis and Improvement of Multiple Sclerosis Following Disease-Modifying Therapies, Health Science Reports (2022)
18. Evaluating the Effects of Epigallocatechin-3-Gallate on Hif-1Α Protein and Rorc Gene Expression in Peripheral Blood Mononuclear Cells in Patients With Multiple Sclerosis, Basic and Clinical Neuroscience (2021)
19. Mir-145 and Mir20a-5P Potentially Mediate Pleiotropic Effects of Interferon-Beta Through Mitogen-Activated Protein Kinase Signaling Pathway in Multiple Sclerosis Patients, Journal of Molecular Neuroscience (2017)
20. The Comparative Analysis of Serum Levels of Midkine in Patients With Multiple Sclerosis and Control Group, Journal of Isfahan Medical School (2013)
21. Evaluation of Edaravone Effects on the Differentiation of Human Adipose Derived Stem Cells Into Oligodendrocyte Cells in Multiple Sclerosis Disease in Rats, Life Sciences (2021)
22. Prognostic Value of Intrathecal Igg Synthesis in Multiple Sclerosis: A Study in 54 Patients, Tehran University Medical Journal (2008)
23. Th1, Th2 and Th17 Cytokine Profile in Patients With Multiple Sclerosis Following Treatment With Rapamycin, Iranian Journal of Immunology (2016)
24. Joint Application of Magnetic Resonance Imaging and Biochemical Biomarkers in Diagnosis of Multiple Sclerosis, Current Medicinal Chemistry (2020)
25. Connection of Mir-185 and Mir-320A Expression Levels With Response to Interferon-Beta in Multiple Sclerosis Patients, Multiple Sclerosis and Related Disorders (2020)
26. Apamin Administration Impact on Mir-219 and Mir-155-3P Expression in Cuprizone Induced Multiple Sclerosis Model, Molecular Biology Reports (2020)
27. Genetically Engineered Mesenchymal Stem Cells: Targeted Delivery of Immunomodulatory Agents for Tumor Eradication, Cancer Gene Therapy (2020)
28. Evaluation of the Expressed Mir‑129 and Mir‑549A in Patients With Multiple Sclerosis, Advanced Biomedical Research (2021)
29. The Serum Level of Midkine in Patients With Multiple Sclerosis and Neuromyelitis Optica, Basic and Clinical Neuroscience (2021)
30. Current Advances in Stem Cell Therapy in the Treatment of Multiple Sclerosis, Reviews in the Neurosciences (2023)
31. Disease Activity in Pregnant and Postpartum Women With Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying Therapies, Neurology: Neuroimmunology and NeuroInflammation (2024)
32. An Integrated Bioinformatics Analysis of the Potential Regulatory Effects of Mir-21 on T-Cell Related Target Genes in Multiple Sclerosis, Avicenna Journal of Medical Biotechnology (2021)
33. Elevated Serum Level of Il-4 in Neuromyelitis Optica and Multiple Sclerosis Patients, Journal of Immunoassay and Immunochemistry (2019)
34. Pure Spinal Multiple Sclerosis: A Case Series of a Possible New Entity, Journal of Neuroimmunology (2025)
35. Cytokine Gene Expression in Newly Diagnosed Multiple Sclerosis Patients, Iranian Journal of Allergy, Asthma and Immunology (2015)
36. Male Sex Is Independently Associated With Faster Disability Accumulation in Relapse-Onset Ms But Not in Primary Progressive Ms, PLoS ONE (2015)
37. Increased Serum Level of Il-37 in Patients With Multiple Sclerosis and Neuromyelitis Optica, Acta Neurologica Belgica (2015)
38. The Effect of Plasma Exchange on the Expression of Foxp3 and Rorc2 in Relapsed Multiple Sclerosis Patients, Iranian Journal of Immunology (2015)
39. Serum Homocysteine Level in Patients With Multiple Sclerosis, Journal of Research in Medical Sciences (2005)
40. Upregulation of Mtor, Rps6kb1, and Eif4ebp1 in the Whole Blood Samples of Iranian Patients With Multiple Sclerosis Compared to Healthy Controls, Metabolic Brain Disease (2020)
41. The Frequencies of Peripheral Blood Cd5+Cd19+ B Cells, Cd3−Cd16+Cd56+ Nk, and Cd3+Cd56+ Nkt Cells and Serum Interleukin-10 in Patients With Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder, Allergy, Asthma and Clinical Immunology (2022)
42. Potential Role of Trace Elements (Al, Cu, Zn, and Se) in Multiple Sclerosis Physiopathology, NeuroImmunoModulation (2021)
43. Identification of Potential Biomarkers in the Peripheral Blood Mononuclear Cells of Relapsing–Remitting Multiple Sclerosis Patients, Inflammation (2022)
44. Cerebrospinal Fluid and Serum Markers of Inflammation in Patients With Multiple Sclerosis, Advances in Neuroimmune Biology (2017)
45. Interleukin-33 Plasma Levels in Patients With Relapsing-Remitting Multiple Sclerosis, Biomolecular Concepts (2017)
46. Comparison of Follicular T Helper Cells, Monocytes, and T Cells Priming Between Newly Diagnosed and Rituximab-Treated Ms Patients and Healthy Controls, Research in Pharmaceutical Sciences (2022)
47. Increased Expression of Lymphocyte Activation Gene-3 by Regulatory T Cells in Multiple Sclerosis Patients With Fingolimod Treatment; [Multiple Sikleroz Hastalarinda Fingolimod Tedavisi Sonucu Duzenleyici T Hucrelerinde Lenfosit Aktivasyon Gen-3 Ekspresyonunda Artis], Turkish Journal of Immunology (2019)
48. The Effect of Ifn-Β Treatment on Plasma Levels of Bdnf and Il-6 in Relapsing-Remitting Multiple Sclerosis Patients, NeuroImmunoModulation (2021)
49. Study of the Correlation Between Mir-106A, Mir-125B, and Mir-330 on Multiple Sclerosis Patients by Targeting Tnfsf4 and Sp1 in Nf-Κb/Tnf-Α Pathway: A Case-Control Study, Cell Journal (2022)
50. Insulin-Like Growth Factor-1 (Igf-1) Levels in Multiple Sclerosis Patients: A Systematic Review and Meta-Analysis, PLoS ONE (2024)